ATOS ATOSSA THERAPEUTICS, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1488039 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-14.8%
TTM EPS YoY31.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-96.9%
ROA-82.1%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets17.8%
Debt / equity0.00x
Current ratio5.35x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.02x
Accruals ratio1.5%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $21.18M | $14.12M | $17.33M | $15.08M | $9.21M |
| SG&A expense | $15.96M | $13.50M | $14.04M | $12.61M | $11.31M |
| Operating income | -$37.14M | -$27.62M | -$31.38M | -$27.69M | -$20.52M |
| Pretax income | -$34.77M | -$25.50M | -$30.09M | -$26.96M | -$20.61M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$34.77M | -$25.50M | -$30.09M | -$26.96M | -$20.61M |
| EBITDA | -$37.12M | -$27.60M | -$31.35M | -$27.68M | -$20.50M |
| EPS (basic) | -4.04 | -3.04 | -0.24 | -0.21 | -0.18 |
| EPS (diluted) | -4.04 | -3.04 | -0.24 | -0.21 | -0.18 |
| Weighted avg. shares (diluted) | 8.61M | 8.39M | 126.08M | 126.62M | 116,950 |
| Balance sheet | |||||
| Cash & equivalents | $41.30M | $71.08M | $88.46M | $110.89M | $136.38M |
| Current assets | $45.62M | $74.46M | $92.22M | $118.20M | $141.24M |
| PP&E, net | — | — | — | — | $20,000 |
| Intangibles | — | — | — | — | $54,000 |
| Total assets | $47.61M | $76.44M | $96.25M | $123.53M | $141.26M |
| Current liabilities | $8.26M | $4.97M | $5.24M | $5.57M | $3.13M |
| Total liabilities | $8.26M | $4.97M | $5.24M | $5.57M | $3.13M |
| Shareholders' equity | $39.35M | $71.48M | $91.02M | $117.96M | $138.14M |
| Shares outstanding | 8.61M | 8.61M | 125.30M | 126.62M | 126.62M |
| Cash flow statement | |||||
| Operating cash flow | -$29.76M | -$21.03M | -$20.94M | -$20.76M | -$16.47M |
| Capital expenditure | $23,000 | $19,000 | $14,000 | $27,000 | $9,000 |
| Free cash flow | -$29.79M | -$21.05M | -$20.95M | -$20.79M | -$16.48M |
| Investing cash flow | -$23,000 | -$19,000 | -$14,000 | -$4.73M | -$9,000 |
| Financing cash flow | $0 | $3.67M | -$1.48M | $0 | $113.30M |
| Depreciation & amortization | $16,000 | $17,000 | $23,000 | $8,000 | $23,000 |
| Stock-based compensation | $2.65M | $2.29M | $4.62M | $6.79M | $5.27M |
| Share buybacks | — | $0 | $1.48M | $0 | — |
Free plan shows the latest 5 periods; Pro shows all 16 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.